Market Research & Consulting
SEED PLANNING

Optimizing Patient Recruitment Strategies in the Japanese Market

A Paradigm Shift from Severity Labels to Pharmacotherapy-Based Screening





Contents & index

1. Executive Summary

While the Japanese healthcare market is globally critical due to its size and quality, it is notoriously difficult for "Patient Recruitment" in market research and clinical trials. A primary cause of failure is the direct application of global screening criteria—specifically subjective labels like "Mild," "Moderate," and "Severe"—which often fail to capture target populations due to cultural, linguistic, and structural nuances.

This report analyzes the root causes of why "Self-Reported Severity" fails in Japan and proposes a **"Pharmacotherapy-Based Screening"** approach as the optimal solution. By using prescribed medications and treatment history as objective proxies for clinical severity, researchers can bypass patient subjectivity and accurately identify target segments.

Drawing on a primary case study of Chronic Obstructive Pulmonary Disease (COPD), alongside validations in Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), and Inflammatory Bowel Disease (IBD), this report demonstrates how to leverage Japan's strict national insurance reimbursement criteria to reverse-engineer clinical severity from prescription data.

2. The Japanese Healthcare Ecosystem and Recruitment Barriers

When designing studies for Japan, global clients often encounter low incidence rates (IR) in screening and contradictory data in main surveys. Understanding the unique structural and psychological factors of the Japanese market is essential to overcoming these issues.

2.1 Structural Factor: Reimbursement Criteria as a "Gatekeeper"

Japan operates under a Universal Health Coverage (UHC) system. To control costs, the Ministry of Health, Labour and Welfare (MHLW) and academic societies establish strict guidelines for prescribing high-cost drugs (biologics, molecular targeted drugs, triple inhalation therapies, etc.).[1]

- **Strict Step Therapy:** Physicians cannot prescribe high-cost drugs solely based on patient preference. For example, Dupilumab (Dupixent) for Atopic Dermatitis is reimbursable only if "adequate treatment with anti-inflammatory topical agents (steroids/tacrolimus) has failed to provide sufficient effect".[4]
- **Implication for Recruitment:** This regulation means **the presence of a specific prescription is objective proof that the patient has failed standard-of-care treatments (i.e., is Moderate-to-Severe)**. Even if a patient self-identifies as "mild" because their symptoms are currently controlled, their prescription history confirms they meet the clinical criteria for higher severity.

2.2 Economic Indicator: The "High-Cost Medical Expense Benefit"

For patients on expensive therapies, Japan's "High-Cost Medical Expense Benefit System" (Kogaku Ryoyohi Seido) is a lifeline. This system caps monthly out-of-pocket expenses based on income.6

While patients often cannot recall their clinical stage (e.g., TNM classification or GOLD stage), they are acutely aware of whether they hold an "Eligibility Certificate for Ceiling-Amount Application" or if they reach their payment cap monthly. This serves as a highly reliable proxy for screening patients on high-cost biologic or advanced therapies.7

2.3 Cultural Factor: Paternalism and "Omakase" Medicine

The physician-patient relationship in Japan retains strong elements of traditional paternalism. While informed consent is growing, many patients, especially the elderly, adopt an "Omakase" (leaving it to the expert) attitude.[10]

- **Information Asymmetry:** Historically, diagnoses like cancer were not always disclosed to patients to protect them from distress. While this is changing, physicians often still avoid emphasizing "severity labels" (e.g., "You are Stage IV") unless necessary, focusing instead on "treatment steps".[10]
- **"Sunao" (Compliance) & Under-reporting:** Japanese patients tend to under-report pain or burden to avoid being seen as "complaining" or troubling the doctor.[13] Consequently, self-reported severity scores often skew lower than the clinical reality.

3. The Trap of "Moderate": Limitations of Subjective Labels

The global standard scale of "Mild, Moderate, Severe" loses objectivity when translated into Japanese ("Keisho, Chutosho, Jusho").

3.1 Linguistic Ambiguity and Central Tendency Bias

In Japanese, "Chutosho" (Moderate) is a vague concept often interpreted by patients as "I am taking medicine, but I am not hospitalized." Clinically, however, "Moderate" can range from fully independent to requiring daily assistance.[14] Furthermore, Japanese respondents exhibit a strong "Central Tendency Bias," avoiding extreme answers. This causes true "Severe" patients to select "Moderate," and "Mild" patients to also select "Moderate," creating significant data noise.

3.2 Low Disease Literacy and Terminology Barriers

Patient understanding of medical terminology is often lower than assumed by global protocols.

This is critical in COPD. The most significant predictor of prognosis is "Exacerbation" (Japanese: Zouaku). However, surveys indicate that less than 50% of Japanese patients recognize the term "Zouaku".13

If a screener asks, "Have you experienced an exacerbation in the past year?", most patients will answer "No," even if they were hospitalized for a "bad cold" that was clinically an exacerbation.13

3.3 The "Silent Sufferers"

Recent patient survey revealed that while ~90% of Moderate-to-Severe COPD patients felt distress in daily life, many accepted it as "old age" or "unavoidable," and did not discuss it with their doctors.13

If these patients are asked, "Is your COPD severe?", they will likely say "No" because they view their condition as a natural part of aging rather than a severe disease state.

4. Case Study: Solutions in Chronic Obstructive Pulmonary Disease (COPD)

COPD represents the most significant gap between patient perception and clinical reality, making it the perfect case study for Pharmacotherapy-Based Screening.

4.1 2024 Guidelines and the Reality of Severity Classification

According to the Japanese Respiratory Society (JRS) Guidelines (6th Ed, 2024 revision) and GOLD 2024, COPD severity is determined by airflow limitation (FEV1), symptoms (mMRC, CAT), and Exacerbation History.1

Crucially, patients with frequent exacerbations are classified as "Group E (Exacerbators)," for whom Triple Therapy (ICS/LAMA/LABA) is strongly recommended.1

4.2 Logic: Determining Severity via Drug Proxies

Patients cannot recall their FEV1% or GOLD stage, but they **recognize the shape and color of their inhaler**. Since Japanese guidelines strictly link drug classes to severity, we can reverse-engineer the patient's status.



Table 1: Pharmacotherapy-Based Recruitment Matrix for COPD

Target Patient (Clinical Definition)	**Patient Self-Perception (Subjective Bias)**	**Recommended Screening Criteria (Drug Proxy)**	**Rationale & Guideline Alignment**
Early / Mild (Group A)	"Healthy" or "Mild"	**LAMA mono or LABA mono** (e.g., Spiriva, Onbrez)	Bronchodilator monotherapy is the first line for low-symptom, low-risk patients.[1]
Symptomatic / Moderate (Group B)	"Mild" to "Moderate"	**LAMA/LABA Combination** (e.g., Anoro, Ultibro)	Prescribed for patients with significant dyspnea or insufficient response to monotherapy. This is the volume zone.
Severe / Exacerbator (**Group E**)	"Moderate" (Underestimated due to adaptation)	**ICS/LAMA/LABA (Triple Therapy)** (e.g., Trelegy, Breztri, Enerzair)	**[Critical]** Japanese labeling restricts Triple Therapy to "COPD with inadequate control on existing therapies." **Usage of this drug defines the patient as 'Severe/Exacerbator' regardless of self-report**.[1]

4.3 Screening Without the Word "Exacerbation"

Since "Zouaku" is poorly understood, screeners must avoid the term.

1. **Direct Question (Ineffective):** "Have you had an exacerbation?" → **High False Negative.**
2. **Drug Proxy (Effective):** "Please select the inhaler you are currently using from these photos."
   - *Selection:* Trelegy, Breztri, etc.
   - *Logic:* Patient is clinically "Group E / Severe Risk" even if they feel "Moderate."
3. **Symptom Description (Supplemental):** Use "patient language" to identify events.
   - *Example:* "Have you experienced a sudden worsening of breathlessness triggered by a cold, requiring an antibiotic drip or extra medication at a hospital?".[13]

5. Cross-Disease Validation (RA, AD, IBD)

The "Drug as Severity Proxy" approach is replicable across other chronic conditions in Japan.

5.1 Rheumatoid Arthritis (RA): The Biologic Barrier

Japan's RA Guidelines (2024) clearly define treatment phases.[2]

- **Phase I:** Methotrexate (MTX) as the anchor.
- **Phase II:** Introduction of Biologics (bDMARDs) or JAK inhibitors (tsDMARDs) only if MTX fails to achieve remission.

  Strategy: Asking "Is your RA severe?" is ineffective. Patients on biologics who are currently in remission may say "Mild." To find "Refractory/Difficult-to-Treat" patients, screen for "Use of self-injection (Bio) or JAK inhibitors," and confirm usage of the "High-Cost Medical Expense Benefit" system.6

5.2 Atopic Dermatitis (AD): Criteria for Systemic Therapy

New guidelines (2024) position systemic therapies (Dupilumab, JAK inhibitors) clearly.3

Insurance requires: "IGA score 3, EASI score 16," AND "inadequate response to strong topical steroids".4

Strategy: Dupilumab prescription = Objective Moderate-to-Severe. There is no need to ask the patient to estimate their body surface area affected; the drug serves as the validation of their severity.

5.3 Inflammatory Bowel Disease (IBD): Digital Tools & "Gaman" (Endurance)

UC patients often under-report stool frequency due to embarrassment. However, many use apps like "IBD Note" to track logs.

Strategy: Avoid vague severity questions. Ask for specific metrics: "Is your stool frequency 6+ times/day?" or "Is there visible blood in more than half of stools?" These map directly to the Lichtiger Index used in guidelines.24 Biologic use (e.g., Entyvio, Stelara) again serves as a proxy for failure of conventional 5-ASA/Steroid therapies.

6. Structural Challenges and Solutions in Recruitment

6.1 The "Referral Letter" Barrier

Japan distinguishes strictly between "Clinics" (primary care, mild) and "Hospitals" (200+ beds, severe). Severe patients are referred to hospitals.[26]

- **Challenge:** Standard web panels are heavily populated by clinic-based (mild) patients. Severe patients treated at university hospitals are underrepresented.
- **Solution:** Must use **Disease-Specific Panels** or recruit via **Patient Advocacy Groups (PAGs)**.

6.2 The Digital Divide in the Elderly (75+)

While internet usage is high, it drops sharply after age 75.[29] Yet, the severe COPD/RA population is concentrated in this age group.[31]

- **Challenge:** Web-only surveys recruit "Active Seniors," introducing selection bias and excluding the bedridden or frail.[33]
- **Solution:** For targets aged 75+, employ **Caregiver Proxies** (recruit the family member managing the care) or use hybrid methods (Paper/Phone).[35]

6.3 Trust Issues and "Guinea Pig" Stigma

"Chiken" (Clinical Trial) can carry a stigma of "human experimentation" in Japan.[36]

- **Solution:** Recruitment materials must emphasize **"Contribution to future medicine"** and **"Data for fellow patients"** rather than monetary incentives. Collaboration with PAGs builds necessary trust, provided compliance guidelines are met.[37]

7. Best Practices: An Implementation Guide

Action 1: Visual & Logic-Based Screeners

Abandon text-only severity questions.

- **Visuals:** Use photos of medications/devices (e.g., inhalers, auto-injectors).
- **Backend Logic:** Do not ask "Are you severe?" Ask "Do you use Drug X?" and tag them as "Severe" in the backend data.

Action 2: Incorporate "System/Regime" Questions

leverage Japan-specific social systems as screening criteria.

- *Q:* "Do you use a 'High-Cost Medical Expense Benefit' certificate?" (Proxy for expensive/advanced therapy).
- *Q:* "Do you hold a 'Designated Intractable Disease (Nanbyo)' certificate?" (Proxy for officially certified severity in IBD/PF, etc.).[39]

Action 3: Transcreation (Not Translation)

Translate concepts, not just words.

- *Global:* "Acute Exacerbation."
- *Japan (Patient-Facing):* "Sudden worsening of symptoms triggered by a cold requiring hospital treatment."
- *Global:* "Moderate."
- *Japan (COPD context):* "Shortness of breath when walking fast on level ground" (mMRC Grade 1-2 equivalent).[17]

Action 4: Hybrid Recruitment Channels

For moderate-to-severe targets, move beyond general consumer panels.

- **Specialized Vendors:** Partner with medical-specialist vendors (Ask Seed for Access).[27]
- **Caregiver Recruitment:** Essential for 75+ populations.
- **PAG Collaboration:** Engage for rare diseases, treating the relationship as a long-term partnership/grant support, not a transactional "fee per head".[37]

8. Conclusion

Success in Japanese patient recruitment requires a fundamental shift: **Stop trusting the patient's subjective words ("I am moderate") and start trusting the objective treatment facts (Drugs & Insurance Certificates).**

The COPD case study proves that while patients may lack disease literacy, they know their medication. By aligning screener logic with Japan's strict reimbursement guidelines, researchers can pierce the veil of cultural ambiguity and reach the true target audience.

Global stakeholders are advised to adopt **"Logic Localization"**—adapting the recruitment criteria to match the local treatment reality—rather than simple linguistic translation of global screeners.

Appendix: Pharmacotherapy Proxy Reference (2025 Outlook)

Therapy Area	Target Severity	Global Question (Ineffective)	Recommended Japan Screener (Effective)	Rationale (Guideline/Insurance)
COPD	Severe / Exacerbator	"Have you had an exacerbation?"	**"Do you use a 3-in-1 inhaler like Trelegy or Breztri?"**	Triple therapy is limited to patients with exacerbation history/poor control.[1]
RA	Moderate-Severe / Refractory	"Is your RA severe?"	**"Do you use injections (Enbrel, Humira) or JAK pills (Rinvoq)?"**	Biologics define Phase II (MTX-inadequate response) patients.[2]

Atopic Derm	Severe / Systemic candidate	"Is your rash widespread?"	**"Are you treated with shots (Dupixent) or oral JAKs (Olumiant)?"**	Systemic tx requires IGA ≥3 and topical failure.[4]
Ulcerative Colitis	Moderate-Severe	"How severe is your UC?"	**"Is stool frequency 6+/day? Is there visible blood?"**	Maps to clinical severity index (Lichtiger) & Biologic eligibility.[24]

Sources

1. COPD 診断と治療のためのガイドライン[第 6 版] および GOLD 2023 report に COPD 治療における吸入ステロイド薬（ICS） ※ 追加併用の考慮についての記載が追加されました。 - GSKPro for Healthcare Professionals, 1 月 16, 2026、 https://gskpro.com/ja-jp/products-info/trelegy/copd/clinical-trail/guideline/
2. RA 診療ガイドライン 2024 の改訂ポイント - 博多リウマチセミナー, 1 月 16, 2026、 http://www.hakatara.net/images/no24/24-3.pdf
3. アトピー性皮膚炎診療ガイドライン 2024 ポイントの解説 - Sanofi campus, 1 月 16, 2026、 https://pro.campus.sanofi/dam/jcr:1f1f1713-a045-47ef-9777-cd2e0b2da1ca/MAT-JP-2408821-10.pdf
4. 最適使用推進ガイドライン デュピルマブ（遺伝子組換え） - 厚生労働省, 1 月 16, 2026、 https://www.mhlw.go.jp/content/12404000/001167635.pdf
5. 1 最適使用推進ＧＬが策定された医薬品の保険適用上の留意事項について （案） 1 概要 最, 1 月 16, 2026、 https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000203078.pdf
6. 関節リウマチに関する医療費支援制度, 1 月 16, 2026、 https://chugai-ra.jp/movie/expenses-support.html
7. 高額療養費制度について - 乾癬ネット, 1 月 16, 2026、 https://www.kansennet.jp/about_care/kougaku/
8. 高額な医療費を支払ったとき | こんな時に健保 | 全国健康保険協会, 1 月 16, 2026、 https://www.kyoukaikenpo.or.jp/g3/sb3030/
9. 高額療養費制度 適用ルール 治療費を支援する制度 - がんを学ぶ, 1 月 16, 2026、 https://www.ganclass.jp/support/medical-cost/rule
10. Thoughts and Behaviors of Chinese and Japanese Doctors when faced with the Death of a Patient: A Qualitative Descriptive Study of Doctors' Responses to a Hypothetical Scenario - NIH, 1 月 16, 2026、 https://pmc.ncbi.nlm.nih.gov/articles/PMC12508314/
11. Patients' preferences for involvement in treatment decision making in Japan - PMC, 1 月 16, 2026、 https://pmc.ncbi.nlm.nih.gov/articles/PMC375530/
12. The Patient's Right to Know of a Cancer Diagnosis: A Comparison of Japanese Paternalism and American Self-Determination, 1 月 16, 2026、 https://contentdm.washburnlaw.edu/digital/api/collection/wlj/id/4510/download
13. 約 9 割の中等症～重症の COPD 患者が日常生活の中で苦しさを感じるが, 1 月 16, 2026、 https://www.sanofi.co.jp/assets/dot-jp/pressreleases/2025/250529.pdf

14. 図表 5 ICF 評価点 (基準)と採点結果 - 0:問題なし 1:軽度の問題 2:中等度の問題 - 厚生労働科学研究成果データベース - 国立保健医療科学院, 1 月 16, 2026、 https://mhlw-grants.niph.go.jp/system/files/2013/131011/201301020A/201301020A0004.pdf
15. 認知症の診断について, 1 月 16, 2026、 http://www.roken.or.jp/wp/wp-content/uploads/2012/09/p012-018.pdf
16. 国内での COPD 治療、追跡調査結果を発表 - 東京医科大学病院, 1 月 16, 2026、 https://hospinfo.tokyo-med.ac.jp/news/release/pdf/release_20151022.pdf
17. COPD の段階的マネージメント - Therapeutic Research は, 1 月 16, 2026、 https://therres.jp/r-open/img/open_202404_1.pdf
18. COPD（慢性閉塞性肺疾患）の原因と診断, 1 月 16, 2026、 https://www.kasai-yokoyama.com/copd/
19. 関節リウマチ診療ガイドライン 2024 改訂 薬物治療アルゴリズム, 1 月 16, 2026、 https://www.hosaka-clinic.com/wordpress/wp-content/uploads/2024/07/RAGL2024_p2.pdf
20. 宮崎善仁会病院 リウマチセンターニュース, 1 月 16, 2026、 https://www.m-zenjin.or.jp/nzenjin/wp-content/uploads/2024/09/RA%E3%82%BB%E3%83%B3%E3%82%BF%E3%83%BC%E3%83%8B%E3%83%A5%E3%83%BC%E3%82%B920240909-cleaned.pdf
21. 明日から使える診療の Tips:『アトピー性皮膚炎診療ガイドライン 2024』をひも解く | Derma times, 1 月 16, 2026、 https://medical-pro.kaken.co.jp/dermatology/derma_times/tips_tomorrow_01.html
22. アブロシチニブ製剤の最適使用推進ガイドライン(既存治療で 効果不十分なアトピー性皮膚炎)について - PMDA, 1 月 16, 2026、 https://www.pmda.go.jp/files/000243655.pdf
23. IBD ノート 炎症性腸疾患（IBD）患者さん向け ... - IBD ステーション, 1 月 16, 2026、 https://www.ibdstation.jp/forpatient/ibdnote/
24. 潰瘍性大腸炎・クローン病診断基準・治療指針, 1 月 16, 2026、 https://www.jsibd.jp/wp-content/uploads/2024/06/9cc2e731dfaed4f7cae4c923d180551b.pdf
25. 潰瘍性大腸炎にはどんなタイプがあるの？ 炎症の範囲 - IBD ステーション, 1 月 16, 2026、 https://www.ibdstation.jp/aboutuc/type.html
26. Overcoming barriers to primary care research in Japan: a call to action - PubMed Central, 1 月 16, 2026、 https://pmc.ncbi.nlm.nih.gov/articles/PMC11937693/
27. Patient Recruitment & Clinical Trial Advertising Services in Japan - 3H メディソリューション, 1 月 16, 2026、 https://3h-ms.co.jp/recruitmentlp-en
28. 調査における疾患患者のリクルートメント方法について –【公式】- アスマーク, 1 月 16, 2026、 https://www.asmarq.co.jp/column/column-cat/how_to/disease-patient/
29. 令和６年度青少年のインターネット利用環境実態調査 調査結果（概要） - こども家庭庁, 1 月 16, 2026、 https://www.cfa.go.jp/assets/contents/node/basic_page/field_ref_resources/9a55b57d-cd9d-4cf6-8ed4-3da8efa12d63/0a26134c/20250328_policies_youth-kankyou_internet_research_results-etc_16.pdf

30. 日本の生成 AI 利用率 26.7%の衝撃：世界に遅れる現状と、エンジニアができること - Qiita, 1 月 16, 2026、https://qiita.com/mhamadajp/items/863899d1ce76d0da651d
31. 関節リウマチってどんな病気？ - 倉敷中央病院, 1 月 16, 2026、https://www.kchnet.or.jp/kchtimes/healthy-living/kenkoukouza/post-2789/
32. 関節リウマチの治療成績 2024 年 2 月 米沢市立病院, 1 月 16, 2026、https://yonezawa-city-hospital.jp/wp-content/uploads/2024/04/%E3%83%AA%E3%82%A6%E3%83%9E%E3%83%81%E7%A7%91_%E9%96%A2%E7%AF%80%E3%83%AA%E3%82%A6%E3%83%9E%E3%83%81%E6%B2%BB%E7%99%82%E6%88%90%E7%B8%BE2024.pdf
33. 高齢者のデジタル対応力、4 つのタイプで解き明かす「格差」と「可能性」の真実 ～デジタル化の波に乗るシニア、戸惑うシニア、それぞれの本音とは～ - NRI 社会情報システム, 1 月 16, 2026、https://www.nri-social.co.jp/sirniors/column/column_32/
34. ネットリサーチモニタの投票行動は世の中の縮図となり得るか｜リサーチ、市場調査ならマクロミル, 1 月 16, 2026、https://www.macromill.com/data_and_insights/researcher_column/article_007.html
35. Magenta Health Japan – Market Research – Market research agency, Tokyo Japan, 1 月 16, 2026、https://www.magentahealthjapan.com/
36. 【製薬・CRO 担当者必見！リアル症例集積の本質に迫る連載#1】治験リクルートの常識を疑え “症例集積に苦戦する疾患”の裏側｜Buzzreach 公式 note, 1 月 16, 2026、https://note.com/buzzreach_note/n/nc67ad07469dc
37. 患者団体との協働に関するガイドライン | 透明性ガイドラインについて | 日本製薬工業協会, 1 月 16, 2026、https://www.jpma.or.jp/basis/patient_tomeisei/aboutguide/kyodo.html
38. Guideline for Collaboration with Patient Organizations, 1 月 16, 2026、https://www.jpma.or.jp/english/code/transparency_guideline/Patient_Organizations/eplg5k00000007n9-att/220915_1.pdf
39. 消化器領域の指定難病：医療費助成申請のための重症度基準詳細解説, 1 月 16, 2026、https://www.kurita-naika.jp/information/20250602
40. 指定難病医療給付制度について - 埼玉県, 1 月 16, 2026、https://www.pref.saitama.lg.jp/a0705/nanbyo/gaiyo.html
41. Healthcare Market Research in Japan | M3.inc, 1 月 16, 2026、https://corporate.m3.com/en/service/market-research/
42. DoctorMill｜Macromill Carenet, Inc. a research company specializing in the Healthcare sector., 1 月 16, 2026、https://www.macromillcarenet.jp/english/doctormill.html